Curating and Analyzing Real-World Data for Critical Care Research in COVID-19 and Beyond
(1437192-05) The CURE Drug Repurposing Collaboratory: Capturing Real-World Clinical Outcome Data to Advance Drug Repurposing and Inform Future Clinical Trials for Diseases of High Unmet Medical Need
Sr. Scientific Director CRITICAL PATH INSTITUTE Simpsonville
Disclosure(s):
Smith Heavner, PhD, RN: No relevant financial relationship(s) to disclose.
With more than 10,000 known diseases and under 3,000 medications approved by the U.S. Food and Drug Administration (FDA), up to 70% of conditions have no FDA approved treatment. Many conditions are treated with “off-label” medications (i.e., drug repurposing) on the basis of lower tiers of evidence (e.g., case reports, expert opinion) or professional organization guidelines, especially in rare and emerging conditions. For some treatments, this reality means safety and effectiveness are not well known. This session describes CURE Drug Repurposing Collaboratory’s (CDRC) collaboration with the SCCM Discovery Network to build sustainable, scalable partnerships to advance drug repurposing research in critical care and beyond. CDRC is a public-private partnership initiated in June 2020 by the Critical Path Institute and the FDA in partnership with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
